Connect with us

Energy & Resources

SFLMAVEN (OTCMKTS: SFLM) Heating Up as Ebay Top Seller Reports Record Setting Performance During March & Move into Emerging ‘MetaVerse’ Space

Published

on

SFLMAVEN (OTCMKTS: SFLM) is heating up in recent trading with a significant surge of volume and beginning to make a move to the upside. The stock is getting noticed and has been under accumulation by a growing shareholder base attracted to the stock by the Company’s rapid growth in sales. SFLM heated up this time last year and ran to highs of $0.02 from a start point of about $0.003. The stock dropped farther since than as gravity fueled by some dilution took its toll. However, there has been a marked increase in trading volume in recent days with dollar volume moving up to several $100,000 per day. SFLM has an attractive share structure here; of the OS, 315 million are restricted and post CEO Joseph Ladin returning 300 million shares to the Company’s treasury, there are just 1,493,770,942 free trading shares as of March 26. 

Business could not be better for SFLM, according to management: “We are having some strong tailwinds in place right now, including our unique ability to meet the needs of jewelry consumers in a context defined by supply chain issues and bare bones inventories for other jewelry sellers. Because we deal in pre-owned luxury estate jewelry and watches, we have no supply chain constraints.” Driven by the Company’s popular Thursday Night Auction events, SFLMAVEN recently reported a record setting performance during the month of March. Earlier this month SFLM reported March 2022 performance data, which was highlighted by 51% year over year sales growth to an annual run rate of over $14.4 million in total topline sales. Highlights include total revenues of $1.21 million in sales for the month of Mar 2022, up 51% year over year, total sales up 49% on a sequential monthly basis, 1,362 items sold, up 66% on a sequential monthly basis and a new Company record for sales. During the month of March 2022, the Company managed to set new multi-decade records in total sales, product pricing, and unit sales volume as demand for high-end goods grows in an environment defined by supply shortages for precious metals, rare goods, and luxury items. 

SFLMAVEN (OTCMKTS: SFLM) the Company’s wholly owned subsidiary, is one the world’s largest online marketplaces for authenticated, luxury goods. Through its wholly-owned subsidiary, SFLMAVEN hosts auctions using eBay’s auction technology. The Company is revolutionizing luxury resale by providing an end-to-end service that unlocks supply from luxury good sellers and creates a trusted, curated online marketplace for buyers globally. Over the past seventeen years, the Company has cultivated a loyal and engaged seller and buyer base through continuous investment in its logistics infrastructure and relationship development. Famous for its Thursday Night Auction events on its top-rated eBay store, SFLMaven has driven over $140 million in sales since inception, earning more than 100k positive reviews along the way. See the Company’s eBay store here. (www.ebay.com/str/sflmavenantiquesjewelryfineart)  

SFLM has a strong management team behind it led by CEO Joseph Ladin, an entrepreneur and successful business executive who was born in Canada and raised in South Florida. He attended the University of Florida and started SFLMaven in 2003.  Mr. Ladin never imagined he’d be in the estate jewelry business. He knew nothing about gemstones, precious metals or diamonds until one day 18 years ago when he submerged himself into learning about antiques and began to sell them online. Joe studied business in college at the University of Florida and it came in handy when he launched his own storefront on Ebay. SFL Maven was formed 18 years ago and today has over $1.1 million in sales each month. Last week, Mr. Ladin returned 300 million shares of common stock to the Company’s treasury as an initial step in the Company’s newly initiated shareholder value protection campaign. 

 

To Find out the inside Scoop on SFLM Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

SFLM

 

SFLMAVEN also recently entered the booming ‘MetaVerse’ space worth $40 billion in 2021. Recently SFLM acquired virtual real estate in Decentraland™ The Company’s plot will be used to found SFLMaven’s metaverse store, which will operate as the first native dealer of high-end vintage digital jewelry NFT items for avatar use in the metaverse. 

The Company recently begun the process of accepting Bitcoin (“BTC”) for purchases of high-end vintage jewelry items both in the real world and digitally within the metaverse. The Company has also begun to diversify its cash and cash equivalents holdings to include scaling exposure to BTC as a line item in its recorded holdings of assets. Management notes that the Company is seeing unprecedented flows of cash from operations in 2022 due to increasing demand, increasing web traffic at its online store, and record participation in SFLMaven vintage jewelry auctions. The Company has also begun to implement its metaverse strategy, which promises to augment sales in 2022, further highlighting the need for alternative payment systems and a diversified process for storing and recording financial assets. 

On April 26 SFLMAVEN announced unaudited performance results for the week ended Thursday, April 21, 2022. Total Sales of $273k for seven days ended Apr 21 Apr 21 Thursday Night Auction Sales of more than 247k. The April 21 auction was highlighted by the sale of a Chopard La Strada 18k gold 16.33ct VS natural diamond cluster link necklace for approximately $12k and a heavy 14k white gold 185.60CT diamond & Fancy cut amethyst wide bracelet for just under $9,700. 

CEO Joseph Ladin stated: “Our core business performance so far in 2022 has afforded us greater strategic latitude to accomplish new goals and expand in new directions. That performance has continued in April with another stellar week that would have been one of our best ever if not for the extraordinary rate of growth we have seen so far in 2022. We look forward to further contributions in that direction from our expansion to accept Bitcoin and our upcoming Metaverse presence. In the meantime, please join us for our next Thursday Night Auction event this week. We have some remarkable pieces up for the bidding!” 

 For more on SFLM Subscribe Right Now!

Currently trading at a $1.6 million market valuation SFLM has 1,809,275,173 shares outstanding (after SFLM’s CEO Joseph Ladin returned 300 million shares of common stock to the Company’s treasury) another 315 million shares are restricted leaving a low float of 1,493,770,942 free trading shares. SFLM got hot this time last year and ran to highs of $0.02 from a start point of about $0.003. The stock dropped farther since then and level out and formed a base in the $0.0009 to $0.0012 range. Currently trending towards the top of that range, there has been a marked increase in trading volume in recent days with dollar volume moving up to several $100,000 per day, and with a significant gap to fill from current levels, growing liquidity and legions of new shareholders who see this one going way higher, a breakout could be imminent. Business could not be better for SFLM, earlier this month the Company reported March 2022 performance data, which was highlighted by 51% year over year sales growth to an annual run rate of over $14.4 million in total topline sales. During the month of March 2022, the Company managed to set new multi-decade records in total sales, product pricing, and unit sales volume as demand for high-end goods grows in an environment defined by supply shortages for precious metals, rare goods, and luxury items. We will be updating on SFLM when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with SFLM.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in SFLM either long or short and we have not been compensated for this article

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Energy & Resources

FREYR Battery (NASDAQ: FREY) Makes Waves as Government Support and Strategic Partnerships Drive Growth

Published

on

FREYR Battery’s (NYSE: FREY) stock experienced a remarkable surge of 20% today, propelled by the company’s ongoing achievements in advanced battery cell production. These significant milestones have garnered increased confidence from prominent analysts such as Adam Jonas from Morgan Stanley, further bolstering the positive sentiment surrounding the company.

The company recently assembled and successfully charged their first batch of semi-automated battery unit cells at their Customer Qualification Plant in Norway. This achievement is a big step forward for FREYR, as it allows them to automate the production process and start testing chargeable cells by the second half of 2023.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

The Norwegian Government is also planning to announce a support package for the battery industry, which could have positive implications for FREYR’s plans. They are considering expanding their factory configuration based on the successful Giga America development model. If things go well, they could start production in 2025.

FREYR’s progress with strategic partnerships is also worth noting. They are currently in discussions with more than 10 potential partners who are evaluating the opportunity to collaborate. Additionally, several companies have shown interest in participating in the project-level equity raise. The company is also working closely with financial institutions to secure the necessary funding by the third quarter of 2023. If all goes as planned, they expect to start production in 2025.

In a recent development, FREYR partnered with a USD $30B Chinese company called “Sunwoda Electronic” who’s engaged in the research, development, manufacturing, and sales of lithium-ion batteries products.

The company also received a signal from a prominent passenger vehicle (OEM) that plans to join forces with FREYR’s strategic energy transition coalition, which already includes industry giants such as Caterpillar, Glencore Plc, Siemens AG, and Nidec Corporation. This partnership is set to forge a strategic alliance with a common goal of collaboratively manufacturing high-quality electric vehicle (EV) batteries specifically designed for passenger vehicles.

The company’s sales pipelines continue to grow rapidly, with strong interest from customers in energy storage systems, commercial mobility, and electric vehicles. They are currently in talks with over 70 potential customers, ranging from power producers to battery technology providers and commercial vehicle manufacturers. The total estimated demand for their battery solutions exceeds 600 GWh by 2030.

Thoughts from major analysts and the retail community:

These advancements haven’t gone unnoticed by analysts and the retail community alike. The latest developments promote an increasingly proactive audience that continues to identify emerging trends and buying opportunities.

One user keenly observed an important development involving Adam Jonas, the Head of Global Auto & Shared Mobility at Morgan Stanley. Jonas recently upgraded his recommendation on the stock and revised the price target to $13, implying a potential increase of 42.2% from the current levels. In addition to the price target upgrade, Jonas also adjusted his position from Equal-Weight to Overweight, indicating a heightened positive outlook on the stock’s performance. This shift in stance further underscores the growing recognition of the company’s potential and highlights the confidence placed in its future prospects.

The analyst is optimistic about the stock’s performance, particularly if the company achieves important commercial milestones mentioned above in the near future.

Deeper dive on Equal-Weight vs. Overweight:
An Overweight rating indicates that the analyst expects the stock to perform better than the average performance of its peers or the overall market. It suggests that the investor should consider allocating a higher weight or exposure to the stock in their portfolio compared to its representation in the market or sector. It implies a positive outlook and an expectation of above-average returns for the stock.

Both rating designations, Equal-Weight and Overweight, are relative assessments and depend on the specific analyst’s opinion and outlook for the stock. It’s important to note that different investment firms or analysts may have their own variations of rating systems, so it’s always beneficial to understand the specific criteria and context used by the analyst providing the rating.

Another user “Mini_Tradewz” believes there’s potential considering the low selling volume against VWAP (9.20), indicating buyers are still present.

What’s VWAP?:

VWAP stands for Volume Weighted Average Price. It is a trading indicator used by traders and investors to calculate the average price at which a particular security has been traded throughout the day, taking into account both the price and the volume of each transaction. VWAP is often used as a benchmark to evaluate the execution quality of trades or to determine the fair value of a security.

The VWAP is calculated by multiplying the price of each transaction by the corresponding trading volume, summing up these values, and dividing the total by the cumulative trading volume. This calculation gives more weight to transactions with higher volume, hence the term “Volume Weighted” in the name.

Traders use VWAP as a reference point to assess whether they are buying or selling a security at a favorable price compared to the average price of the day. It can also help identify potential support or resistance levels in the market. VWAP is commonly used by institutional investors, algorithmic traders, and day traders to guide their trading decisions and assess market trends.

Additional Posts by Other Users:

https://twitter.com/FISKERWHALE/status/1673403217109983233?s=20

Conclusion:

FREYR Battery (NYSE: FREY) presents an intriguing investment opportunity, driven by its notable progress in collaboration with the Norwegian government, robust strategic partnerships, and a growing market landscape. However, it’s crucial to conduct thorough research and exercise due diligence before making any investment decisions. This article serves as a compilation of recent news, insights from both retail and analysts, but it’s essential to form your own conclusions based on personal evaluation and analysis.

We will update you on FREY when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by Geralt on Pixabay

 

 

Continue Reading

BioPharma

Cosmos Holdings Inc (NASDAQ: COSM) Huge Short Position Panicks as COSM Rockets Up the Charts

Published

on

Cosmos Holdings Inc (NASDAQ: COSM) is rocketing up the charts northbound since reversing off $0.0675 lows earlier this month where we first gave the heads up on COSM at around a dime in our article here. Since than COSM has rocketed northbound recently surpassing $0.60 per share with speculators pointing at $1 as the next stop. In our previous article on COSM on November 13 when COSM was $0.10 we stated: “COSM was trading well over $3 at the beginning of this year but has been heavily shorted since than with current estimates of well over 5 million shares sold short and almost the entire public float sold short. 

While COSM has been heavily shorted into oblivion, the Company is actually doing quite well recently reporting revenues for the 3 months ended September 30 were $12 million. The Company is successfully developing their business recently closing a deal with Iberica, a European Airline, for in flight distribution of their products. The CEO has bought millions of shares at current levels and COSM is beginning to go viral on social media trending on the sub reddit Short Squeeze, Number #1 on Stocktwits and multiple videos being made on YouTube about a massive short squeeze taking place in small caps. 

COSM Friday December 2, 4PM Close Update: COSM had a wild trading day on Friday dropping to $0.42 in the morning before rocketing up to $0.61 highs. This was followed by another drop to the $0.47 range before COSM rocketed up in late afternoon trading, closing at $0.53 on 205 million shares traded. COSM was up 33% on the day on around $110 million in dollar volume. COSM is setup for an enormous week ahead, looking to overtake the $0.845 from Monday and embark on a blue-sky breakout with $1 as the first stop. We gave the heads up on COSM when the stock was below $0.10 per share at the beginning of November. We will be updating on COSM as soon as anything new happens so make sure you are subscribed to Microcapdaily by entering your email in the box below.  

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

No alternative text description for this imageCosmos Holdings Inc (NASDAQ: COSM) is a global healthcare group that was incorporated in 2009 and is headquartered in Chicago, Illinois. Cosmos Health is engaged in the nutraceuticals sector through its own proprietary lines of products “Sky Premium Life” and “Mediterranation.” Additionally, the Company is operating in the pharmaceutical sector through the provision of a broad line of branded generics and OTC medications and is involved in the healthcare distribution sector through its subsidiaries in Greece and UK serving retail pharmacies and wholesale distributors. Cosmos Health is strategically focused on the R&D of novel patented nutraceuticals (IP) and specialized root extracts as well as on the R&D of proprietary complex generics and innovative OTC products. Cosmos has developed a global distribution platform and is currently expanding throughout Europe, Asia and North America. Cosmos Health has offices and distribution centers in Thessaloniki and Athens, Greece and Harlow, UK. 

The Number #2 post on the subreddit ShortSqueeze currently is titled: COSM about to test resistance. A pump through $0.66 and lift off to over $1.00 is possible now. 

In another post on COSM in the subreddit ShortSqueeze rubio2430 states: “$COSM you cant make this stuff up. this baby is ready for space. the shorts are burying themselves on the daily. constant pr’s, growing fundamentals, no plans on dilutions, dual listing on upstream soon—the list goes on! 

nimble_broccoli replied: Why this is a good play: 

1.) Extremely tiny Marketcap 2.) CEO buying 15’000’000 shares 3.) Good fundamentals, unlike other plays, they actually sell products valued around 10x the valuation. Q1/22 was profitable. 4.) Getting momentum on social media (Reddit Twitter, YT) 

Next catalysts: -Info that they will not be delisted from NASDAQ -Degen and Retail FOMO kicking in -Shorts starting to cover their asses 

In addition, consider this: The stock was somewhere between USD 2 and USD 12 the past ~8 years. Most Hodlers bought back then, do you think they will sell now? Do your own thinking but if one of my stocks dropped 80+ % i d not sell, i d just hope for a miracle or ride it out. Thus, not many regular buy&hold holders of the stock are expected to sell. 

Cosmos operates in the business of full-line pharmaceutical wholesale distribution and serves approximately 1,500 independent retail pharmacies and 40 pharmaceutical wholesalers in Greece region by providing brand-name and generic pharmaceuticals, over-the-counter medicines, vitamins and nutraceuticals. Cosmos invests in technology to enhance safety, distribution and warehousing efficiency and reliability. Specifically, the Company operates a fully automated warehouse system with three robotic systems, two ROWA™ types and one A-frame type, that ensure 0% error selection rate, accelerate order fulfillment, and yield higher cost-efficiency in our distribution center. Cosmos has 3 operating subsidiaries including:

SkyPharm
Sky Pharm SA is headquartered in Thessaloniki, Greece. Sky Pharm trades the excess amounts of about 500 medicines that can be exported within the EU countries. We buy from Greek wholesale pharmaceutical companies and multinational pharmaceutical manufacturers, and export to European markets where demand and prices are substantially higher.
.
DHN
Decahedron Ltd. is a pharmaceutical wholesaler incorporated in the UK in August 2011. It is audited by the MHRA under European GDP (Good Distribution Practices). They are also a full member of the EAEPC and have been audited by TÜV on their behalf.
.
Cosmofarm
Founded in 1994, Cosmofarm is a fully licensed pharmaceutical wholesale company operating in the greater Athens area. The company is approved and authorized by the National Organization for Medicines under Good Distribution Practices to distribute a comprehensive range of pharmaceutical products. Cosmofarm’s core activity is sourcing, procuring, and distributing branded.
.
To Find out the inside Scoop on COSM Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

COSM

Image

COSM business is strong and Q3 highlights include closing a $7.5M capital raise via public offering and signing an exclusive agreement to market and distribute Nickelodeon’s SpongeBob and PAW Patrol kids’ vitamins in Greece and Cyprus, aiming to reach out 11,000 pharmacies and 120 wholesalers in Greece and 780 pharmacies in Cyprus. They also executed a letter of intent for a strategic co-venture agreement with Smart for Life (SMLF) to cross market products and services in their reciprocal markets. COSM also entered into an LOI to acquire ZipDoctor Inc., and entered into an agreement with Virax Biolabs (VRAX), to become the distributor of Monkeypox Virus Real-Time PCR Detection Kits, having the exclusive distribution rights for Greece and Cyprus, with the opportunity to distribute the test kits across Europe on a non-exclusive basis. SkyPharm officially launched its first Sky Premium Life products on Amazon in the United States. Cosmos targets having all 85 SKUs listed on Amazon by year end. COSM entered into an LOI to acquire Pharmaceutical Laboratories CANA S.A., and another LOI to acquire LIFE NLB, Ltd.’s product portfolio, including Bone-Vio® and Bone-X, related to bone health targeting the human gastrointestinal microbiome. 

Last week COSM announced its Sky Premium Life luxury food supplement brand will be sold on Ronda, the official inflight magazine of the airline company Iberia of BRITISH AIRWAYS group. Ronda is available free of charge to the over 10 million passengers who fly Iberian Airlines annually. Iberia Airlines, majority owned by British Airways, has a fleet of 147 aircrafts and engages in over 600 daily flights. 

https://twitter.com/nxtplse/status/1597365583934545920

For More on COSM Subscribe Right Now!

Currently trading at a $36 million market valuation COSM os is 92,008,281 the Company recently reported Q3 Revenues of $12 million down a bit from the same time last year due to a high variation in FX differences between EUR and GBP to USD. COSM was trading over $4 this time last year however OS has increased substantially since then.  COSM is an exciting opportunity in small caps; the stock was shorted into oblivion and currently there are minimum 5.8 million shares short and was way oversold to pennies and it looked as if it would definitely get delisted by the Nasdaq however, led by able CEO Grigorios Siokas, Cosmos is fighting back. Mr. Siokas continues to buy more COSM at current price levels, putting his money where his mouth is as COSM rockets towards $1 which is now just a day and half away if the stock continues up at the same trend.  We will be updating on COSM when more details emerge so make sure you are subscribed to Microcapdaily.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in COSM either long or short and we have not been compensated for this article.

Continue Reading

BioPharma

Cosmos Holdings Inc (NASDAQ: COSM) Heating Up as Co Looks to Take on Massive 5 million Share Short Position

Published

on

Cosmos Holdings Inc (NASDAQ: COSM) is making a rapid move up the charts since recent reversing off $0.0675 lows. The stock was trading well over $3 at the beginning of this year but has been heavily shorted since than with current estimates of well over 5 million shares sold short and almost the entire public float sold short. COSM is quickly emerging as the latest short squeeze at the top of speculators watch lists and is currently trending on stocktwits and the sub reddit ShortSqueeze on Reddit. 

The Company is fighting back against the shorts and planning a lawsuit and CEO Grigorios Siokas recently put his money where his mouth is when he bought 12,500,000 shares of the stock at $0.12 average for about $1.5 million. While in danger of being delisted from the Nasdaq if they don’t get the stock price back over $1 by the end of November the Company is doing well recently reporting its first ever net income on $13,208,504 in revenues for the 3 months ended June 30, 2022. Cosmos is also acquiring ZipDoctor Inc. from American International Holdings Corp (AMIH) 

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Cosmos Holdings Inc (NASDAQ: COSM) is an international healthcare group that was incorporated in 2009 and is headquartered in Chicago, Illinois. On August 2, 2022, the Company filed a Fictitious Firm Name Certificate in Nevada to do business under the name Cosmos Health, Inc. and will seek shareholder approval at its annual shareholders meeting scheduled for December 2, 2022 to amend its Articles of Incorporation for the name change. Cosmos Health is engaged in the nutraceuticals sector through its own proprietary lines of products “Sky Premium Life” and “Mediterranation.” Additionally, the Company is operating in the pharmaceutical sector through the provision of a broad line of branded generics and over-the-counter (“OTC”) medications and is involved in the healthcare distribution sector through its subsidiaries in Greece and UK serving retail pharmacies and wholesale distributors.  

Cosmos operates in the business of full-line pharmaceutical wholesale distribution and serves approximately 1,500 independent retail pharmacies and 40 pharmaceutical wholesalers in Greece region by providing brand-name and generic pharmaceuticals, over-the-counter medicines, vitamins and nutraceuticals. Cosmos invests in technology to enhance safety, distribution and warehousing efficiency and reliability. Specifically, the Company operates a fully automated warehouse system with three robotic systems, two ROWA™ types and one A-frame type, that ensure 0% error selection rate, accelerate order fulfillment, and yield higher cost-efficiency in our distribution center. Cosmos has 3 operating subsidiaries including:

SkyPharm
Sky Pharm SA is headquartered in Thessaloniki, Greece. Sky Pharm trades the excess amounts of about 500 medicines that can be exported within the EU countries. We buy from Greek wholesale pharmaceutical companies and multinational pharmaceutical manufacturers, and export to European markets where demand and prices are substantially higher. The …
DHN
Decahedron Ltd. is a pharmaceutical wholesaler incorporated in the UK in August 2011. It is audited by the MHRA under European GDP (Good Distribution Practices). They are also a full member of the EAEPC and have been audited by TÜV on their behalf. They import and export branded, generic and …
Cosmofarm
Founded in 1994, Cosmofarm is a fully licensed pharmaceutical wholesale company operating in the greater Athens area. The company is approved and authorized by the National Organization for Medicines under Good Distribution Practices to distribute a comprehensive range of pharmaceutical products. Cosmofarm’s core activity is sourcing, procuring, and distributing branded

https://twitter.com/ChairmanOtc/status/1590877348752420866

To Find out the inside Scoop on COSM Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

COSM

ImageOn August 22 Cosmos provided a business update and reported financial results for the second quarter and six months ended June 30, 2022. Revenues were $13,208,504 for the 3 months ended June 30, 2022 compared to $14.8 million for the same period last year. 

Greg Siokas, Chief Executive Officer of Cosmos Health, stated, “We increased our profitability for the first half of 2022 due to the increase of gross profit margin to 14.2% from 11.5% for the respective period of 2021. This increase is attributed mainly to the organic growth of our proprietary nutraceutical brand, Sky Premium Life® (“SPL”). We achieved positive income from operations of $0.2 million for the first half of 2022 compared to a loss of $3.1 million in the same period last year and positive EBITDA of $0.8 million for the first half of 2022 compared to a loss of $2.8 million for the same period last year. Gross profit increased by 23.0% to $3.7 million for the six months ended June 30, 2022. We continue to carefully manage expenses and reduced operating expenses by nearly 43.7% and 41.9% for the three and six months ended June 30, 2022, respectively. During the quarter, we launched a new premium line of nutritional supplements, Mediterranation. The Mediterranation line uses organic herbs and plant extracts such as crataegus, hibiscus, dittany of Crete, oregano, mastic and kritamos, found in specific regions in Greece and the Mediterranean. These unique formulations contain a proprietary blend of vitamins and minerals and are made with the highest quality raw materials. There is high demand among consumers for supplements that utilize high quality Mediterranean ingredients, such as polyphenols, which possess antioxidant and anti-inflammatory properties. We expect the launch of the Mediterranation line will further enhance our growth strategy and we look forward to expanding the product line into new global markets through our growing distribution channels. We also launched our SPL products on Amazon Singapore and are in the process of launching on Amazon United States and Amazon Canada in the third quarter of 2022. These new markets provide an untapped growth opportunities and new audiences for our proprietary SPL brand. Our goal is to grow our portfolio of branded nutraceuticals and reach up to 150 SKUs by the end of 2022.” 

Earlier this year Cosmos announced an LOI to acquire ZipDoctor Inc. from American International Holdings Corp (AMIH). AMIH will continue to manage all aspects of the day-to-day operations of ZipDoctor including product development, marketing, and operational support. ZipDoctor Inc., is a direct-to-consumer subscription-based telemedicine platform, that expects to provide its customers affordable, unlimited, 24/7 access to board certified physicians and licensed mental and behavioral health counselors and therapists. ZipDoctor’s online telemedicine platform will be available to customers across the United States and offers English and Spanish coverage with virtual visits taking place either via the phone or through a secured video chat platform. 

On October 17, 2022, Cosmos entered into a Securities Purchase Agreement with certain institutional investors (the “Purchasers”), pursuant to which the Company agreed to issue and sell, in a public offering, an aggregate of $7,500,000 of securities, consisting of (i) 62,500,000 shares of Common Stock, (ii) pre-funded Warrant in lieu of shares of Common Stock, and (iii) warrants to purchase 125,000,000 shares of Common Stock (the “Common Warrants” and collectively with the Pre-Funded Warrants, the “Warrants”).  Under the terms of the Purchase Agreement, the Company agreed to sell one share of its Common Stock or a Pre-Funded Warrant and two Common Warrants for each share of Common Stock or Pre-Funded Warrant sold at a unit price of $0.12.  For each of 15,662,603 Pre-Funded Warrant sold in the Offering, the number of shares of Common Stock offered were decreased on a one-for-one basis. 

https://twitter.com/AirGoodman24/status/1591938222548189186

 For More on COSM Subscribe Right Now!

Currently trading at a $10 million market valuation COSM is the latest potential short squeeze at the top of speculators watch lists. With $35 million in current liabilities and an inability to collect on accounts receivables that currently stand at over $25 million COSM stock has lagged even as the Company reports its first ever net income on $13,208,504 in revenues for the 3 months ended June 30, 2022. The short position on COSM has grown to well over 5 million shares short and currently the entire public float is sold short. Now that the cat is out of the bag and the stock is surging northbound COSM short squeeze should be at the top of small cap speculators watch lists. We will be updating on COSM when more details emerge so make sure you are subscribed to Microcapdaily.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in COSM either long or short and we have not been compensated for this article.

Continue Reading

Trending

© All rights reserved.

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.